Plain-English translation of NCT07620275 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new type of treatment that uses your own immune cells to fight multiple myeloma—a cancer of blood-forming cells. The medication is designed to be generated directly in your body and to target cancer cells in a new way. Researchers want to understand whether this treatment is safe and how well it works for people whose myeloma has come back or stopped responding to standard therapies.
Multiple myeloma can be very difficult to treat once it stops responding to standard medications. This trial exists because researchers believe that using your own immune cells in this new way might offer hope to patients who have run out of other treatment options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the medication as an intravenous infusion (through a needle in your vein). The trial is small—only 9 patients will be enrolled—and doctors will carefully watch for safety and how well the treatment works. You should expect close monitoring and follow-up visits to track how your body responds to this new therapy.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
China